Introducing ScoliCare ® Denver Colorado | A New Hope for Individuals with Scoliosis

Individuals with scoliosis in Colorado now have access to a world-leading scoliosis treatment center with the opening of ScoliCare Denver Colorado. The clinic aims to transform the lives of patients with a non-surgical scoliosis specific approach, state-of-the-art facilities, and a highly experienced healthcare team.

Scoliosis affects up to 5% of young people and up to 68% of those over 60 and its prevalence is growing in the USA due to the aging population. The condition is characterized by an abnormal curvature of the spine.

ScoliCare clinics provide in-depth assessments and treatment plans for infants, children, adolescents, and adults. Treatment options include the world-leading ScoliBrace® bracing system and ScoliBalance®, a physiotherapeutic scoliosis-specific exercise program.

“Traditionally surgery was thought to be the only option for people with scoliosis however now, if we catch the curve early enough, we can prevent surgery,” explained Dr. Chris Gubbels D.C., Head Clinician at ScoliCare Denver Colorado. “We recognize the difficulties scoliosis can present, and our dedicated team is devoted to supporting patients throughout their treatment journey to achieve the best possible outcomes and enhance quality of life.”

Patient Success Story: Eric’s Journey

Dr. Gubbels has many years of experience treating scoliosis in collaboration with ScoliCare. One of his patients, Eric was first diagnosed at 11 years old and his curve continued to progress. While in college Eric injured his spine in a rock climbing accident which impacted his scoliosis and he was faced with physical discomfort and emotional distress. He began looking for treatment options as he was worried he would end up needing surgery. That’s when he found Dr. Gubbels who diagnosed Eric with severe scoliosis. With a customized ScoliBrace® and a tailored ScoliBalance® exercise program provided by ScoliCare, Eric’s curve significantly improved. Eric’s experience with Dr. Gubbels and his treatments have since inspired him to pursue a healthcare career.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”